A big driver of speculative value for development stage biotech is the potential for interest from big pharma.....

Look at a chart for RLYP, it was a yoyo from $12ish to $45 down to $20 back up to $40....back down to $12.50 or so as recenlty as this spring, and then a buyout at $32 was announced.

Relypsa hasn't been around as long as Resverlogix, but with the IPO buzz in 2014 and early 2015...combined with a Nasdaq listing, it had a much higher profile, and it was regularly getting trashed on sites like Twitter and Stocktwits by users I suspect of being industry hacks...and I don't doubt for a second (although it is just opinion) that short selling is used to drive the PPS down at times when industry players are in accumulation mode.

I just wonder....could RVX be a target as well? With all the potential indications for RVX 208...CVD, Kidney, Diabetes, Alzheimers etc.....I'm almost starting to think of Apebetalone as being almost like Aspirin....but Aspirin on steroids. Of course with Dart and Hepa we have major league players that would need to be satisified and at least in the case of Monsier Dart...I would have to think that his involvement is a bit of a flag given what I've read about him....he doesn't just like to win, he wants to destroy the opposition from what I've seen.

Anyway...just mindless musings that might provide fodder for some conversation.